🙏 Thank you for your incredible interest in our recent paper! I am excited to dive into the details of our study on maladaptive repair post-AKI and unlock the secrets of kidney recovery. Let's explore together! #ResearchInterest" @ScienceMagazine https://t.co/MVq8pKHcTI

Urinary biomarkers that predict the progression of diabetic kidney disease! ASCI member @KidneydrChirag & team evaluated over 1000 participants with T2D and suggest EGF and UMOD as candidate biomarkers in diabetic kidney disease. See full report: https://t.co/ap5JWIXCN8

I will give a talk at Hopkins India Conference on Panel: Non-Communicable Diseases. Hoping for a great turnout! #HopkinsIndiaConference - via #Whova event app

So excited to have these folks joining new Osler members!! #Oslerpride

Brilliant talk!

STARTING NOW Toward Complex Understanding of Kidney Function in AKI: Role of Biomarkers, Sex Differences and the Tropics; ISN- KSN Joint Session 🕗 9:45 am 🗣️ Chi-yuan Hsu, @KidneydrChirag , @enigma165vivek , Marlies Ostermann 👥 Girish Narayen, Hyeong Cheon Park, Prem P Varma

It was lovely to catch up with @SamiAlasfar and meet the accomplished transplant faculty at @MayoClinicNepAZ Thank you for the wonderful visit!

Accurate diagnosis of acute tubulointerstitial nephritis (AIN) often requires a kidney biopsy. This study found that an AIN diagnostic model retained discrimination in two validation cohorts but needed recalibration to account for local AIN prevalence. https://t.co/2eYL77Q3y9

I hope people will use the AIN calculator to differentiate AIN from ATN on AKI consults. Let us know if you have questions or additional suggestions. @dmoledina

This important advance was greatly enabled by superstars who are developing kidney biopsy registries at their institutions @dmoledina @StevenMenez

🚨 Exciting Opportunity Alert! 🚨 Johns Hopkins Nephrology is now accepting applications for our prestigious #Transplant Fellowship ! Advance your career with cutting-edge training in one of the nation’s leading programs 📩 Apply or get more info: dmalhor2@jhu.edu- Dr. Malhotra

The Whiting School of Engineering at @JohnsHopkins is hiring: - 80 early-career faculty in AI - 20 Bloomberg Distinguished Professors in domain-specific AI clusters - 10 targeted AI BDPs - 40 faculty in bioengineering & other engn. disciplines + new large building/HPC

Congratulations to our graduating fellows @hopkinsneph! 🎓👏 Your hard work paid off & we are so proud of your accomplishment! Best of luck in your next chapter! 🌟 Special shoutout to @Elena_Cervants for Teaching of the Year & @Patel_DipalM for Mentor of the Year awards! 🌟

We will discuss how to best implement the evidence from the novel agents in the diabetic CKD to the transplant setting to slow GFR decline in the graft and reduce cardiovascular death #sglt2 #glp1

New @hopkinsneph study investigates potential remedy for kidney donor shortage. @KidneydrChirag https://t.co/LjQFanV12u

Careful study just out, led by @KidneydrChirag + @yumeng_wen that shows something I would never have believed not long ago -- that deceased donors who were on dialysis during their terminal hospitalization can provide kidneys that do well after transplant.

Our prior work has shown that extremely low fractional excretion of sodium ; FeNA of <0.25% (not <1% as patients with cirrhosis are <1%) is diagnostic of HRS. Combining urine NGAL for ATN and urine FeNA for HRS can facilitate management in cirrhosis. @scoca1 @hswapnil

In conclusion, urine NGAL is a valuable tool for differentiating ATN in patients with AKI and cirrhosis. Future studies should evaluate real-world impacts of NGAL testing and establish guidelines for its use in various clinical contexts. @VelezNephHepato @JenZ4NGAL

Limitations: 1) Universal NGAL cutoff may not be appropriate for all patients. 2) HRS definitions varied across studies. 3) ATN/HRS diagnoses were clinical, not biopsy-confirmed. 4) Biomarker assays and reporting methods differed.

Median optimal cutoff for urine NGAL to diagnose ATN was 220 mg/g creatinine. NGAL is approved for clinical use in Europe/Asia & recently received FDA approval for pediatric use in the US.

We included 11 studies with 1219 patients. Pooled sensitivity of urine NGAL for diagnosing ATN was 81%, specificity 82%, & area under the receiver operating characteristic curve was 0.88.